Supporting data for “The Impact of Omicron Breakthrough Infections on COVID-19 Vaccine-Generated Immunogenicity”

This study aims to investigate the immunological impact of a single SARS-CoV-2 Omicron breakthrough infection following the third homologous COVID-19 booster dose (CoronaVac or BNT162b2), with a primary focus on assessing whether such infections enhance vaccine-induced humoral and cellular immune memory relative to pre-infection levels.The study also explores several key dimensions of hybrid immunity. First, it examines whether the hybrid responses, arising from three homologous vaccine doses followed by an Omicron breakthrough infection, differ between children/adolescents and adults, and recipients of CoronaVac and BNT162b2. Second, it evaluates whether a fourth antigenic exposure via Omicron breakthrough infection confers additional immunological benefits in triple-vaccinated individuals compared to those who remain uninfected after their third dose. Lastly, the study investigates whether hybrid immunity offers enhanced immunological protection compared to vaccine-induced immunity alone.Samples from 103 children (ages 3-10), 187 adolescents (ages 11-17), and 232 adults (ages 18-69) recruited in Hong Kong were included in the final analysis.The dataset includes tabular data used in the study, covering SARS-CoV-2 variant dynamics in Hong Kong, daily and weekly case counts during the COVID-19 pandemic, demographic information of study participants, the study timeline, and measurements of humoral and cellular immune responses.